Compare Crispr Therapeutics AG (CRSP) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs KeyCorp — how do they compare? Crispr Therapeutics AG trades at $50.73 (market cap $5.06B), while KeyCorp trades at $20.1 (market cap $21.16B). The key difference: KeyCorp is far larger — about 4.2× Crispr Therapeutics AG's market cap, and KeyCorp pays a 4.14% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and KeyCorp for 66 Days on average.
| CRSP | KEY | |
|---|---|---|
Market Cap | $5.06B | $21.16B |
Volume | 1,678,371 | 16,207,672 |
Sector | Health | Financials |
52-Week High | $74.92 | $23.99 |
52-Week Low | $44.34 | $16.78 |
Typical Hold Time | 77 Days | 66 Days |
Enterprise Value | $3.48B | $34.34B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
KeyCorp (KEY) trades at $20.1, down 0.2% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The stock shows attractive valuation with a P/E of 11.6 and a P/B of 1.22, supported by a strong net income margin of 26.72%. Recent corporate actions include a dividend payment scheduled for September 2026 and key executive appointments aimed at strengthening operations.
The outlook is positive with a consensus price target of $25.00, implying significant upside, driven by loan growth and net interest margin expansion. Risks include competitive pressure from peers raising dividends and macroeconomic sensitivity to interest rate changes. Earnings momentum and institutional buying provide a solid foundation for potential appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
